Nanomedicine (London, England)最新文献_第4页

Advances in the application of lipid nanocapsules and nanostructured carriers in the treatment of lung cancer. 脂质纳米胶囊及纳米结构载体在肺癌治疗中的应用进展。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-04 DOI: 10.1080/17435889.2025.2555169

Maria Irujo, Alice Gaudin, Mileidys Perez-Alea, Isabelle Texier

{"title":"Advances in the application of lipid nanocapsules and nanostructured carriers in the treatment of lung cancer.","authors":"Maria Irujo, Alice Gaudin, Mileidys Perez-Alea, Isabelle Texier","doi":"10.1080/17435889.2025.2555169","DOIUrl":"https://doi.org/10.1080/17435889.2025.2555169","url":null,"abstract":"Lung cancer remains the leading cause of cancer-related deaths worldwide, with limited curative options, particularly in advanced stages. Lipid-based nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid nanocapsules (LNCs), have emerged as promising drug delivery platforms owing to their biocompatibility, versatility, and potential for pulmonary administration. This review highlights recent advances in lipid nanocarriers for lung cancer therapy, with a particular focus on NLCs and LNCs. We discuss key formulation strategies, including solvent-free processes and the use of FDA-approved excipients, as well as advances in drug encapsulation, combination therapies, and surface engineering. We also examine the integration of reverse micelle architectures, which enables the co-encapsulation of hydrophilic and lipophilic agents within a single nanocarrier. Despite encouraging preclinical data, clinical translation of lipid-based nanocarriers, particularly NLCs and LNCs, remains limited due to challenges in large-scale manufacturing, biodistribution variability, rapid clearance, and lack of analytical standardization. We critically examine these barriers and discuss promising solutions such as Quality-by-Design approaches, lung-on-chip models, and advanced characterization tools. Finally, we outline future directions to bridge laboratory innovation and clinical translation, emphasizing the potential of lipid nanocarriers to enhance therapeutic efficacy and patient safety in lung cancer treatment.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-21"},"PeriodicalIF":3.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can automated gold nanoparticle synthesis drive the next wave of biomedical innovation? 自动化的金纳米粒子合成能推动下一波生物医学创新吗？

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-06-05 DOI: 10.1080/17435889.2025.2514424

Masoud Negahdary, Ngoc Nhu Vu, Samuel Mabbott

引用次数: 0

Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines. 考虑聚乙二醇的免疫原性：克服聚乙二醇化纳米药物问题的策略。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI: 10.1080/17435889.2025.2538423

Kouichi Shiraishi

引用次数: 0

Beyond biologics: fungal polysaccharides as dual-function materials for nanomedicine. 超越生物制剂：真菌多糖作为纳米药物的双重功能材料。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI: 10.1080/17435889.2025.2540775

Mengting Wu, Wenjun Zhang, Hui Song, Yang Hu, Wenlan Li

{"title":"Beyond biologics: fungal polysaccharides as dual-function materials for nanomedicine.","authors":"Mengting Wu, Wenjun Zhang, Hui Song, Yang Hu, Wenlan Li","doi":"10.1080/17435889.2025.2540775","DOIUrl":"10.1080/17435889.2025.2540775","url":null,"abstract":"Fungal polysaccharides exhibit a unique dual role in nano-delivery systems as both bioactive agents and functional carrier materials. Their intrinsic biocompatibility, biodegradability, and immunomodulatory properties enable applications in cancer therapy, immunoregulation, inflammation control, and nutrient delivery. As active components, their therapeutic efficacy is often limited by poor solubility and low bioavailability - issues that can be overcome via nanotechnology strategies such as encapsulation in nanoparticles, nanogels, and nanoemulsions. When used as carriers, fungal polysaccharides offer high drug-loading capacity, tunable surface chemistry, and inherent immune-targeting potential. They enable controlled release, improved stability, and synergistic effects in combination therapies and vaccine adjuvants. However, challenges remain in structural standardization, reproducibility, and understanding structure - activity relationships - particularly regarding higher-order conformations and their biological implications. This review summarizes recent advances in fungal polysaccharide-based nano-delivery systems, emphasizing their structural attributes, formulation strategies, and multifunctional therapeutic roles. It also outlines future directions, including smart carrier design, stimuli-responsiveness, and scalable production. A deeper understanding of their structural biology will guide the rational development of safe and efficient polysaccharide-based nanoplatforms for precision medicine.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2275-2289"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook. 用于mRNA和蛋白质治疗的新兴聚合纳米载体：设计、挑战和临床前景。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-08-05 DOI: 10.1080/17435889.2025.2542110

Chloe Forenzo, Noah Arnold, Jessica Larsen

{"title":"Emerging polymeric nanocarriers for mRNA and protein therapeutics: design, challenges, and clinical outlook.","authors":"Chloe Forenzo, Noah Arnold, Jessica Larsen","doi":"10.1080/17435889.2025.2542110","DOIUrl":"10.1080/17435889.2025.2542110","url":null,"abstract":"As the healthcare landscape rapidly evolves to include advanced drug delivery methods with better cellular targeting and more efficient delivery, polymeric nanocarriers have emerged to close translational gaps. Acting on the central dogma of molecular biology, mRNA and protein therapeutics can offer curative potential for various debilitating diseases. Considering these advancements, polymeric nanocarriers have been widely explored preclinically in delivering both proteins and mRNA for various disease therapies. This review introduces how the next generation of polymeric nanocarriers can be designed for protein therapeutics, including some advantages and disadvantages as well as specific design considerations for mRNA vs protein delivery. The evolution of these polymeric nanocarriers is then examined, and the current landscape and emerging trends are presented. Finally, we provide an outlook on the clinical translation of polymeric nanocarrier delivery of mRNA and proteins, including a future perspective for the field. Despite the preclinical promise of these delivery systems in both mRNA and protein constructs, clinical translation is underwhelming. Continued development of polymeric nanocarriers is underway and early clinical trials have provided a foothold into translation for this technology. A key challenge for polymeric nanomedicine is bridging the gap between promising preclinical data and successful clinical translation.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2357-2374"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging anti-inflammatory nanosystems targeted to the brain. 针对大脑的新兴抗炎纳米系统。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-08-26 DOI: 10.1080/17435889.2025.2552103

Arun Kumar Mahanta, Avinash Gothwal, Bivek Chaulagain, Chinenye Edith Muolokwu, Benjamin Tagoe, Babita Lamsal, Matheus Belin, Jagdish Singh

{"title":"Emerging anti-inflammatory nanosystems targeted to the brain.","authors":"Arun Kumar Mahanta, Avinash Gothwal, Bivek Chaulagain, Chinenye Edith Muolokwu, Benjamin Tagoe, Babita Lamsal, Matheus Belin, Jagdish Singh","doi":"10.1080/17435889.2025.2552103","DOIUrl":"https://doi.org/10.1080/17435889.2025.2552103","url":null,"abstract":"The neuroinflammation hypothesis suggests that neuroinflammation plays an important role in the progression of neurodegenerative diseases. Neuroinflammation is induced by several factors such as stimulatory signals derived from injured/dying cells, aggregated/modified proteins, and inflammatory mediators, including both proinflammatory and anti-inflammatory compounds produced by infiltrating immune cells such as microglia and astrocytes. Controlling the neuroinflammation in the brain might be a fruitful therapeutic strategy to manage the different kinds of neurodegenerative disorders. The delivery of anti-inflammatory agents to the brain is one of the challenging tasks in managing neuroinflammation due to the presence of the blood-brain barrier (BBB), which restricts the entry of the anti-inflammatory agent to the brain. With the advancement of nanoscience and nanotechnology, nanoparticle-based therapeutics are drawing great attention over conventional therapies, including high biocompatibility, more precise targeting, and the ability to cross the BBB. This review summarizes the recent progress in nanotechnology to deliver anti-inflammatory agents to the brain for the management of neurodegenerative disorders associated with neuroinflammation.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":"20 17","pages":"2237-2255"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Repairing and preserving the cellular powerplant with nanotechnology. 用纳米技术修复和保存细胞动力装置。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-05-26 DOI: 10.1080/17435889.2025.2510188

John Soukar, Kanwar Abhay Singh, Akhilesh K Gaharwar

引用次数: 0

Influenza virus-like particles presenting Toxoplasma gondii dense granule protein 7 protect mice from lethal ME49 challenge. 呈递刚地弓形虫致密颗粒蛋白7的流感病毒样颗粒保护小鼠免受致命的ME49攻击。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-08-13 DOI: 10.1080/17435889.2025.2546769

Jie Mao, Hae-Ji Kang, Su-In Heo, Fu-Shi Quan

{"title":"Influenza virus-like particles presenting Toxoplasma gondii dense granule protein 7 protect mice from lethal ME49 challenge.","authors":"Jie Mao, Hae-Ji Kang, Su-In Heo, Fu-Shi Quan","doi":"10.1080/17435889.2025.2546769","DOIUrl":"10.1080/17435889.2025.2546769","url":null,"abstract":"Aim: Toxoplasma gondii dense granule antigen 7 (GRA7) is a membrane-associated protein expressed across parasite life cycle and represents a promising vaccine target. This study aimed to develop a GRA7-based virus-like particle (VLP) vaccine and assess its protective efficacy.Materials & methods: GRA7 VLPs were constructed using an influenza M1 scaffold via the baculovirus expression system. Female BALB/c mice were immunized intranasally three times and orally challenged with lethal T. gondii ME49 cysts. Humoral and cellular immune responses, brain inflammation, and parasite burden were evaluated at 40 days post-infection. Body weight reduction and survival rate were monitored after challenge.Results: GRA7 VLPs induced robust T. gondii-specific IgG in serum after immunization. Following challenge with cysts, elevated antibody levels were detected in intestinal, fecal, and brain tissues, accompanied by enhanced activation of IgG-secreting cells, germinal center B cells, memory B cells, as well as CD4+ and CD8+ T cells in antigen-restimulated splenocytes of vaccinated mice. Notably, vaccinated mice exhibited 100% survival and sustained body weight, alongside a marked reduction in cerebral pro-inflammatory cytokines and parasite cyst burden.Conclusion: GRA7 VLPs confer strong systemic and mucosal immunity and significant protection against chronic toxoplasmosis, underscoring their potential as a promising vaccine platform.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2309-2320"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging self-assembled peptide hydrogels for enhanced wound healing. 新兴的自组装肽水凝胶促进伤口愈合。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-08-13 DOI: 10.1080/17435889.2025.2544535

Zixin Yang, Yinglu Wang, Hu Zhu

{"title":"Emerging self-assembled peptide hydrogels for enhanced wound healing.","authors":"Zixin Yang, Yinglu Wang, Hu Zhu","doi":"10.1080/17435889.2025.2544535","DOIUrl":"10.1080/17435889.2025.2544535","url":null,"abstract":"Wound healing, particularly in chronic conditions such as diabetic ulcers, burns, and pressure injuries, represents a highly intricate and clinically challenging process. These wounds frequently exhibit persistent pathological inflammation, disrupting conventional healing trajectories and significantly compromising patient well-being. Consequently, the development of innovative therapeutic interventions is urgently needed. Self-assembling peptide-based hydrogels have emerged as novel biomaterials, demonstrating exceptional promise in wound management. This article reviews recent advancements in the design and application of self-assembling peptide-based hydrogels, with a focused analysis of their roles in antibacterial activity, hemostasis, and enhancing tissue regeneration. Engineered to exhibit injectability, controlled drug release, spatiotemporal targeting, stimuli-responsive behavior, and biocompatibility, these hydrogels enable precise, dynamic, and patient-tailored therapeutic strategies. By integrating peptide self-assembly with biomedical insights, this article highlights how peptide-based hydrogels address critical limitations in conventional wound care, offering scalable solutions to improve healing outcomes.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2217-2236"},"PeriodicalIF":3.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144839231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanovesicular ultra-deformable transferosomes and transgelosomes for ocular drug delivery. 用于眼部药物传递的纳米泡状超变形转移体和转胶体。

IF 3.9

Nanomedicine (London, England) Pub Date : 2025-09-01 Epub Date: 2025-05-26 DOI: 10.1080/17435889.2025.2510197

Debadatta Mohapatra, Timothy W Corson

引用次数: 0